In this final deep dive episode, Stuart Elborn turns to healthcare systems and policy. He discusses the importance of registries, data sharing, and service organisation, alongside social and funding factors that shape equitable cystic fibrosis care, ending with a global vision for cystic fibrosis management over the next decade.

Timestamps:

00:00 – Introduction

01:08 – Healthcare delivery

03:33 – National registries

05:04 – New challenges

06:35 – Equitable care

08:51 – Regional initiatives

10:40 – What's next?

In this second deep dive episode, Stuart Elborn explores the future landscape of cystic fibrosis treatment beyond modulators. From mRNA and gene editing to inhaled therapies and phenotype-driven care, this episode examines how close we are to truly personalised medicine in cystic fibrosis.

Timestamps:

00:00 – Introduction

01:22 – Treatment gaps

03:13 – Extrapulmonary complications

04:14 – Novel therapies

06:04 – Delivery routes

07:33 – Personalised medicine

The evolving understanding of OA is reshaping how we diagnose, manage, and support patients. As research advances, OA is increasingly recognised as a complex condition influenced by inflammation, biomechanics, genetics, and lifestyle. This shift in perspective is transforming how OA is identified, managed, and experienced across the care pathway. Early intervention remains essential, before irreversible joint damage occurs. With personalised care, interdisciplinary support, and empowering strategies such as education and lifestyle modification, patients can take a more active role in their OA journey. Emerging tools and a proactive clinical mindset are paving the way for improved outcomes and a more positive future.

Topics covered:

· Redefining osteoarthritis beyond the "wear and tear "concept
· The window of opportunity in early OA
· Empowering patients through education and interdisciplinary care

OA is no longer just a "wear and tear" condition. It's a complex, multifactorial disease shaped by inflammation, biomechanics, genetics, and lifestyle. Early diagnosis and timely intervention can shift the course, preventing progression and unlocking the body's potential for self-healing. Today's OA care is moving beyond symptom management. Personalised treatment, interdisciplinary support, and patient empowerment through education and lifestyle changes are redefining what's possible. With emerging tools and a fresh clinical mindset, the future of OA management is proactive, hopeful, and tailored to each individual.

Topics covered:

· The complexity of pain, beyond biology
· The power of validation in patient care
· Self-healing as a new paradigm for patient's empowerment

In this first deep dive, Stuart Elborn reflects on the major scientific breakthroughs of his career, and how laboratory discoveries have transformed cystic fibrosis care. He discusses lessons from pivotal CTFR modulator trials, the role of consensus guidelines, and the challenges of caring for an ageing cystic fibrosis population.

Stuart Elborn joins the EMJ Podcast for a quickfire discussion on modern cystic fibrosis care. From CFTR modulators to antimicrobial resistance and personalised medicine, he shares concise insights into the biggest shifts shaping cystic fibrosis outcomes today.

Byrne discusses Dova's recent Late Breaker at the United European Gastroenterology (UEG) Week 2025, where AI re-analysis uncovered treatment effects missed by human readers. He explains how AI may soon become integral to clinical trial design, regulatory review, and drug approval, while predicting how AI-human partnerships will define the future of gastroenterology.

Timestamps:
01:05 – AI in the TITRATE trial
03:18 – Validating clinical endpoints
04:16 – AI and human readers
16:53 – The next frontier in gastrointestinal AI